











































Evolutionary dependencies show the paths to cancer
development
Citation for published version:
Taylor, MS 2020, 'Evolutionary dependencies show the paths to cancer development', Nature Genetics.
https://doi.org/10.1038/s41588-020-00728-4
Digital Object Identifier (DOI):
https://doi.org/10.1038/s41588-020-00728-4
Link:






Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
Evolutionary dependencies show the paths to cancer development 1 
 2 
Martin S. Taylor 3 
martin.taylor@igmm.ed.ac.uk 4 
MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of 5 
Edinburgh, UK. 6 
 7 
 8 
Patterns of co-occurring and mutually-exclusive mutations reveal synergistic interactions 9 
between cancer driver genes. A new study functionally confirms these interactions and builds 10 
the pairwise relationships into networks of pathway disruption that have better predictive 11 
power than relying on specific mutations. 12 
 13 
Cancers are clonally expanding populations of cells in which the normal regulation of cell division 14 
and behaviour is undermined. That dysregulation is inherited by daughter cells and is thought to be 15 
facilitated by a small number of driver mutations. Genome sequencing studies comparing samples of 16 
cancer and normal cells from the same patient have been hugely successful at identifying the most 17 
commonly occurring driver mutations1. While it appears that most cancers have between one and ten 18 
principal drivers2, it is also apparent that these mutations don’t simply work in an additive manner to 19 
transform normal cells into cancer. Writing in this issue, Mina et al3 set out to develop the idea that 20 
some driver mutations cooperate and so tend to co-occur in cancers, whereas others would be 21 
functionally redundant and tend to occur mutually-exclusively. 22 
 23 
Studying the patterns of mutation co-occurrence and mutual-exclusivity are collectively referred to as 24 
evolutionary dependency (ED) analysis4–8. This new work substantially develops the concept beyond 25 
just pairwise dependencies, it systematically tests both assumptions of and predictions from ED, and 26 
gives a taste of the future insights that may be obtained from this style of analysis. 27 
 28 
Functionally validated dependencies 29 
Standing on the shoulders of The Cancer Genome Atlas (TCGA)1, Mina et al3 curated a list of 30 
recurrently mutated genes and their putative driver mutations. With a broad brush these were 31 
annotated as either oncogenes that drive cancer by dysregulated activity or gain of function, or tumour 32 
suppressor genes, where loss of activity enables cancer growth. 33 
 34 
In an important validation of these driver annotations and proof-of-principal for later analyses, the 35 
authors turned to publicly available data from high-throughput gene essentiality screens of cancer 36 
derived cell-lines. These screens measure the relative fitness of cells - based on their ability to divide - 37 
after using short hairpin RNAs or CRISPR editing to deplete the products of a target gene9–12. 38 
Knowing the driver mutations already present within each cell-line, the authors asked if, as expected, 39 
depleting an oncogene with an activating driver mutation reduces cell fitness more than depleting the 40 
same gene in a cell-line that does not have the driver mutation. This worked remarkably well, 41 
confirming that the oncogene driver mutations were an important component of cell-line fitness, and 42 
to a lesser extent an equivalent strategy also validated tumour suppressor genes. 43 
 44 
Having functionally validated many of the driver mutations they scored all pairwise combinations of 45 
drivers for co-occurrence and mutual-exclusion in the TCGA samples, finding a compelling excess of 46 
both patterns - suggesting a wealth of ED relationships.  47 
 48 
A key insight was that the gene essentiality screens could be used to test these evolutionary 49 
dependencies and probe the nature of their interactions. For a pair of genes with an ED relationship, 50 
they identified cell-lines that contained driver mutations in both genes (double mutants), either gene 51 
(single mutants) or neither gene (wild-types), and asked how they responded to the depletion of one of 52 
the genes in the pair. Depleting a gene from a pair with co-occurring mutations tended to produce a 53 
much greater reduction in fitness for the double mutant cell-lines than for the single mutants (Fig. 1), 54 
supporting the notion of synergy between co-occurring driver mutations.  55 
 56 
For pairs of driver mutations that tend to occur mutually-exclusively in cancers, depleting the mutated 57 
gene in single mutant cell-lines was found to be highly detrimental, more so than in double-mutant 58 
cell-lines. This supports the expectation that mutually-exclusive mutations are often redundant 59 
perturbations of the same cellular pathway. 60 
 61 
Genetics has taught us to treasure our exceptions13. For the functional validation of co-occurring 62 
drivers there was a single prominent outlier, whereas ED predicted synergy between KRAS and 63 
STK11, the essentiality assays consistently point in the opposite direction, suggesting that STK11 64 
mutations reduce a cell’s need for KRAS driver mutations. Amongst mutually-exclusive driver pairs 65 
the exceptions were common, approximately 30% of significant essentiality assays indicating driver 66 
synergy, rather than ED implied redundancy. Reconciling these exceptions may provide greater 67 
insights than the confirmatory results, as they likely reflect the influence of the tumour 68 
microenvironment on driver gene interactions and could point to targetable cancer vulnerabilities. 69 
 70 
Pieces of larger puzzles  71 
Pairwise evolutionary dependencies are pieces of a larger puzzle. Mina et al3, used ED to build 72 
“axes”, networks of co-dependency and mutual-exclusivity, the aim being to classify cancers by the 73 
combinations of pathway perturbations that recurrently drive cancer development. Classification by 74 
axis appears to be better at predicting prognosis and drug response than stratifying on a single key 75 
driver mutation. Some of the drug responses in particular, such as the PARP-inhibitor sensitivity of 76 
PIK3CA/NFE2L2 double-mutants, would not have been predicted nor readily detected without axis 77 
based stratification. 78 
 79 
The ED and functional validation approaches could be applied to other related puzzles such as 80 
whether distinct driver mutations in the same gene are functionally equivalent and contribute to the 81 
same axis. As cancer driver mutations appear to be common in non-cancer clonal expansions of cells 82 
that are a typical feature of aging14,15, a comparison of ED axes between cancers and non-cancer 83 
clones may capture the distinctions between benign clonal expansion and cancerous transformation. 84 




Fig. 1 | Paths of cancer development revealed by evolutionary dependency. a Patterns of 89 
significantly co-occurring or mutually-exclusive driver mutations (filled) identified for pairs of genes 90 
from cancer cohorts. b Gene product depletion in cell-lines often confirms synergy between co-91 
occurring driver mutations and redundancy for mutually-exclusive mutations. Only one gene of the 92 
ED pair is depleted (red border) and the relative fitness compared between cell-lines stratified by the 93 
combined driver status (driver=filled, wild-type=open) of each gene. c Pairwise relationships can be 94 
built into networks, within which clusters of co-occurring genes define an axis of cancer development. 95 
d Classifying cancers by axis can have greater predictive power than using single driver genes. 96 
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